Beta-thalassemia Clinical Trial
Official title:
Prevalance and Risk Factors for Complications in Children With B- Thalassemia Major
Worldwide, there are more than 60,000 births annually of serious forms of thalassemia .The
World Health Organization considers thalassemia to be a major health burden.
Beta- thalassemia is a group of recessively inherited disorders of hemoglobin synthesis
characterized by reduced synthesis of the ß-globin chain caused by a mutation. The homozygous
state results in severe anemia which needs regular blood transfusion.
Thalassemia is the most common monogenic disorder in the world .Thalassemia major
(beta-thalassemia) affects a significant segment of the population in certain areas of the
world. Alterations in migration patterns have changed the geographic distribution of this
disease and made it a worldwide health problem with a high frequency in Africa, India,
Southeast Asia and the Mediterranean area.
The combination of transfusion and chelation therapy has dramatically extended the life
expectancy of these patients, thus transforming thalassemia from a rapidly fatal disease of
childhood to a chronic illness compatible with a prolonged life. On the other hand, frequent
blood transfusions leading to iron overload and the chronic nature of the disease have
contributed to a whole new spectrum of complications in adolescents and young adults
suffering from thalassemia major.
Complications associated with beta thalassemia, aside from the aforementioned anemia, are as
follows
- Extramedullary hematopoiesis
- Asplenia secondary to splenectomy
- Medical complications from long-term transfusional therapy - Iron overload and
transfusion-associated infections (eg, hepatitis) Increased risk for infections
resulting from asplenia (eg, encapsulated organisms such as pneumococcus) or from iron
overload (eg, Yersinia species))
- Cholelithiasis (eg, bilirubin stones) Study of the prevelance and risk fators
responsible for thalassemia complication can help in adopting appropriating strategies
for management of these complication.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00069862 -
Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia
|
Phase 1/Phase 2 | |
Completed |
NCT00733811 -
Efficacy Study of the Use of Sequential DFP-DFO Versus DFP
|
Phase 4 | |
Completed |
NCT05506358 -
Evaluation of Low-cost Techniques for Detecting Sickle Cell Disease and β-thalassemia in Nepal and Canada
|
N/A | |
Withdrawn |
NCT04938635 -
Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia
|
Phase 2 | |
Active, not recruiting |
NCT03655678 -
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia
|
Phase 2/Phase 3 | |
Completed |
NCT06239389 -
Comparison Of Efficacy And Safety Of Thalidomide Vs Hydroxyurea In Thalassemia Patients: A Single-Centre Pilot Study.
|
Phase 2 | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Completed |
NCT03271541 -
A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia
|
Phase 2 | |
Terminated |
NCT02274233 -
Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia
|
Phase 1 | |
Completed |
NCT01206075 -
Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major
|
N/A | |
Recruiting |
NCT05567458 -
A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.
|
Phase 2 | |
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Completed |
NCT03961828 -
Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus
|
Phase 4 | |
Recruiting |
NCT06065189 -
Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major
|
Early Phase 1 | |
Recruiting |
NCT04143724 -
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
|
Phase 2 | |
Terminated |
NCT03381833 -
A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia
|
Phase 2 | |
Completed |
NCT02268409 -
ACE-536 Extension Study - Beta Thalassemia
|
Phase 2 | |
Not yet recruiting |
NCT01996683 -
Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)
|
N/A | |
Active, not recruiting |
NCT01016093 -
Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients
|
Phase 2/Phase 3 | |
Completed |
NCT01039636 -
Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload
|
Phase 1 |